PD-1/PD-L1-IN 7

2374856-75-2

691.61

10 mM in DMSO

Anti-infection; Immunology/Inflammation

PD-1/PD-L1-IN 7 is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 has anticancer and antiviral functions.
IC50 & Target: IC50: 0.213 nM (Human PD-1/PD-L1 protein/protein interaction)
In Vitro: PD-1/PD-L1-IN 7 (compound 139) enhances IFN-gamma and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. PD-1/PD-L1-IN 7 also enhances the frequency of GrB+ cells among HBV-specific CD8+ and CD4+ T cells. The ability of PD-1/PD-L1-IN 7 to enhance the antiviral functions of HBV-specific CD8+ and CD4+ T cells in vitro is comparable to those of Durvalumab.
In Vivo: PD-1/PD-L1-IN 7 (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. PD-1/PD-L1-IN 7 significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model.